Geron to Participate at Upcoming Investor Conferences in March 2025

About this update from Geron Corporation

FOSTER CITY, Calif. --(BUSINESS WIRE)-- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced that members of the management team are scheduled to participate in fireside chats at the following investor conferences: TD Cowen 45th Annual Health Care Conference Monday, March 3 rd at 3:10pm ET ( Boston, MA ) Leerink Global Healthcare Conference Monday, March 10 th 3:00pm ET ( Miami, FL ) Barclays 27th Annual Global Healthcare Conference Tuesday, March 11 th 10:30am ET ( Miami, FL ) A live webcast of each fireside chat will be available through the Investors & Media section of the Geron’s website under Events . A replay of the webcast will be archived and available on Geron’s website for 30 days. About Geron Geron is a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer. Our first-in-class telomerase inhibitor RYTELO® (imetelstat) is approved in the United States for the treatment of certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion dependent anemia. We are also conducting a pivotal Phase 3 clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF), as well as studies in other hematologic malignancies. Inhibiting telomerase activity, which is increased in malignant stem and progenitor cells in the bone marrow, aims to potentially reduce proliferation and induce death of malignant cells. To learn more, visit www.geron.com or follow us on LinkedIn. View source version on businesswire.com : https://www.businesswire.com/news/home/20250221535654/en/ Aron Feingold Vice President, Investor Relations and Corporate Communications Kristen Kelleher Associate Director, Investor Relations and Corporate Communications [email protected] [email protected] Source: Geron Corporation

View stock analysis, news, and events for Geron Corporation